# US 2008/0306271 A1 · Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306271 A1
- Document ID: US20080306271A1
- Status: Published application
- Kind: A1
- Application number: 12/094,304
- Filed: 2006-12-18
- Published: 2008-12-11
- Earliest claimed: 2005-12-20
- Inventors: Jozsef Neu; Istvan Greiner; Janos Csabai; Sandor Garadnay
- Web page: https://patentgrep.com/patent/US20080306271A1

## CPC

- C07D 211/02: Preparation by ring-closure or hydrogenation
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 211/32: by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a novel, industrially realizable and economically preferable process for production of highly pure 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl piperidine hydrochloride, i.e., donepezil hydrochloride shown in the following reaction scheme, in Polymorph (I) morphological crystal form. (I) In one of the key steps of the process, during the hydrogenation 5,6-dimethoxy 2-(pyridine-4-yhnethylene)indan-1-one hydrochloride is saturated using Pd carbon to get 4-[(5,6-dimethoxy-1-indanon)-2-yl]-methyl piperidine at more than 97% HPLC purity. In the crystallization step donepezil-hydrochloride is crystallized from an aqueous alcoholic solvent to get Polymorph (I) in at least 99.95% HPLC purity.

## Claims

### Claim 1

A process for the preparation of highly pure Polymorph (I) donepezil hydrochloride of Formula I with
hydrogenating of 5,6-dimethoxy-2-(pyridine-4-ylmethylene)indane-1-one salt intermediate of Formula IV, and subsequent
benzylating of the obtained 4-[(5,6-dimethoxy-1-indanon)-2-yl]-methyl piperidine intermediate of Formula V, and subsequent
salt-forming steps with reacting donepezil base of Formula VI, and subsequent re-crystallizing of the obtained donepezil hydrochloride of Formula I from a solution containing a short carbon chain alcohol,
which process comprises:
a. accomplishing the said hydrogenating of 5,6-dimethoxy-2-(pyridine-4-yl methylene)indan-1-one hydrochloride of Formula IV in the presence of charcoal Pd catalyst, and
b. accomplishing the said salt-forming steps with reacting donepezil base of Formula VI by acidic acid, then extracting the acetic acidic salt into aqueous phase, then transforming it again to donepezil base in the presence of a base, then transforming the latter into donepezil hydrochloride of Formula I in the presence of hydrogen chloride, and
c. accomplishing the said re-crystallizing with precipitating the Polymorph (I) donepezil hydrochloride product from aqueous alcoholic solution containing 2-18% water.

### Claim 2 (depends on 1)

The process of claim 1 wherein the said hydrogenating comprises the application of charcoal containing 5-15% palladium as a catalyst

### Claim 3 (depends on 2)

The process of claim 2 wherein the said hydrogenating further comprises the application of 4-6 atm. overpressure and temperature at 60-80C.°.

### Claim 4 (depends on 1)

The process of claim 1 wherein the said salt-forming steps comprise reacting the donepezil base by acetic acid in ethyl acetate solution and transferring donepezil acetate into aqueous phase.

### Claim 5 (depends on 1)

The process of claim 1 wherein the said re-crystallizing comprises resolving donepezil hydrochloride in aqueous methanol containing 3-5% (v/v) water.

### Claim 6 (depends on 1)

The process of claim 1 wherein the said re-crystallizing comprises that the aqueous methanolic solution of donepezil hydrochloride is added to the methyl-tert-butyl-ether precipitating agent containing Polymorph (I) seeds.
